MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

Cancer Epidemiology and Prevention

Schottenfeld, D. (2006) · doi:10.1093/acprof:oso/9780195149616.001.0001 · Cited by 3,376 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · see citing works

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · see citing works

Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma

Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2003) · JAMA · doi:10.1001/jama.289.11.1421 · Cited by 579 · see citing works

Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology

M�ller, A. M. S., Ihorst, G., Mertelsmann, R. H., & Engelhardt, M. M. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0939-7 · Cited by 488 · see citing works

Steroid hormone receptors in breast cancer management

Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438 · see citing works

Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer

Li, C. I. (2003) · JAMA · doi:10.1001/jama.289.24.3254 · Cited by 415 · see citing works

MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting

Bond, G. L., Hu, W., & Levine, A. J. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 310 · see citing works

Multistep carcinogenesis of breast cancer and tumour heterogeneity

Beckmann, M. W., Niederacher, D., Schnürch, H.-G., Gusterson, B. A., & Bender, H. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050128 · Cited by 301 · see citing works

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome

Bougeard, G., Baert-Desurmont, S., Tournier, I., Vasseur, S., Martin, C., Brugières, L., Chompret, A., Paillerets, B. B., Stoppa‐Lyonnet, D., Bonaïti‐Pellié, C., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.037952 · Cited by 216 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Gene: From a Molecular and Cellular Explanation to Clinical Effect

Bond, G. L., Hu, W., & Levine, A. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0825 · Cited by 176 · see citing works

The Role ofP53andMDM2Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma

Yuan, H., Miao, X., Zhang, X., Ding, F., Luo, A., Guo, Y., Tan, W., Liu, Z., & Lin, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1460 · Cited by 174 · see citing works

Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression

Kinyamu, H. K., & Archer, T. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5867-5881.2003 · Cited by 157 · see citing works

Genetic polymorphisms in cell cycle regulatory genesMDM2 andTP53 are associated with susceptibility to lung cancer

Zhang, X., Miao, X., Guo, Y., Tan, W., Zhou, Y., Sun, T., Wang, Y., & Lin, D. (2005) · Human Mutation · doi:10.1002/humu.20277 · Cited by 156 · see citing works

Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor α and SP proteins

Stoner, M. A., Wormke, M., Saville, B., Samudio, I. J., Qin, C., Abdelrahim, M., & Safe, S. H. (2003) · Oncogene · doi:10.1038/sj.onc.1207201 · Cited by 147 · see citing works

Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer

Lind, H., Zienolddiny, S., Ekstrøm, P. O., Skaug, V., & Haugen, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21872 · Cited by 144 · see citing works

Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites

Petz, L. N., Ziegler, Y., Schultz, J. R., Kim, H., Kemper, J. K., & Nardulli, A. M. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2003.11.008 · Cited by 142 · see citing works

Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma

Chen, W. Y., Hankinson, S. E., Schnitt, S. J., ROSNER, B. A., Holmes, M. D., & Colditz, G. A. (2004) · Cancer · doi:10.1002/cncr.20499 · Cited by 136 · see citing works

Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County.

Bernstein, L., & Ross, R. (1992) · PubMed · Cited by 134 · see citing works

The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.

Sheikh, M. S., Shao, Z. M., Hussain, A., & Fontana, J. A. (1993) · PubMed · Cited by 127 · see citing works

Recommendations on Predictive Testing for Germ Line p53 Mutations Among Cancer-Prone Individuals

Li, F. P., Garber, J. E., Friend, S. H., Strong, L. C., Patenaude, A. F., Juengst, E. T., Reilly, P. R., Correa, P., & Fraumeni, J. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.15.1156 · Cited by 126 · see citing works

A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells

Arva, N. C., Gopen, T., Talbott, K. E., Campbell, L. E., Chicas, A., White, D. E., Bond, G. L., Levine, A. J., & Bargonetti, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505203200 · Cited by 122 · see citing works

Association Between MDM2–SNP309 and Age at Colorectal Cancer Diagnosis According to p53 Mutation Status

Menin, C., Scaini, M. C., Salvo, G. L. D., Biscuola, M., Quaggio, M., Esposito, G., Belluco, C., Montagna, M., Agata, S., D’Andrea, E., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj054 · Cited by 121 · see citing works

Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review

Dietel, M., Lewis, M. A., & Shapiro, S. (2005) · Human Reproduction · doi:10.1093/humrep/dei043 · Cited by 114 · see citing works

The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck

Alhopuro, P., Ylisaukko‐oja, S. K., Koskinen, W. J., Bono, P., Arola, J., Järvinen, H. J., Mecklin, J., Atula, T. S., Kontio, R., Mäkitie, A. A., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.031260 · Cited by 114 · see citing works

p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.

Phelps, M., Darley, M., Primrose, J. N., & Blaydes, J. P. (2003) · PubMed · Cited by 108 · see citing works

Abnormal expression of MDM-2 in breast carcinomas

Bueso-Ramos, C., Manshouri, T., Haidar, M. A., Yang, Y. S., McCown, P., Ordóǹez, N. G., Glassman, A. B., Sneige, N., & Albitar, M. X. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806499 · Cited by 103 · see citing works

mdm2 gene alterations and mdm2 protein expression in breast carcinomas

Marchetti, A., Buttitta, F., Girlando, S., Palma, P. D., Pellegrini, S., Fina, P., Doglioni, C., Bevilacqua, G., & Barbareschi, M. (1995) · The Journal of Pathology · doi:10.1002/path.1711750106 · Cited by 103 · see citing works

DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy

van de Vaart, P. J. M., Belderbos, J. S. A., de Jong, D., Sneeuw, K. C. A., Majoor, D. M., Bartelink, H. G. M. M., & Begg, A. C. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2 · Cited by 102 · see citing works

Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.

Frébourg, T., Kassel, J., Lam, K. T., Gryka, M. A., Barbier, N., Andersen, T. I., Børresen‐Dale, A., & Friend, S. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6413 · Cited by 97 · see citing works

Estrogen Receptor/Sp1 Complexes Are Required for Induction ofcadGene Expression by 17β-Estradiol in Breast Cancer Cells

Khan, S., Abdelrahim, M., Samudio, I. J., & Safe, S. H. (2003) · Endocrinology · doi:10.1210/en.2002-0149 · Cited by 96 · see citing works

Improving cancer therapy by non-genotoxic activation of p53

Laı́n, S., & Lane, D. P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00063-7 · Cited by 95 · see citing works

The New York Cancer Project: Rationale, Organization, Design, and Baseline Characteristics

Mitchell, M. K. (2004) · Journal of Heredity · doi:10.1093/jurban/jth116 · Cited by 91 · see citing works

Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines

Danel, L., Menouni, M., Cohen, J. H. M., Magaud, J., Lenoir, G., Revillard, J., & Saez, S. (1985) · Leukemia Research · doi:10.1016/0145-2126(85)90125-0 · Cited by 79 · see citing works

Reproductive Factors and Risk of Intermediate- or High-Grade B-Cell Non-Hodgkin’s Lymphoma in Women

Nelson, R. A., Levine, A. M., & Bernstein, L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1381 · Cited by 76 · see citing works

Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.

Gudas, J. M., Nguyen, H., Klein, R. C., Katayose, D., Seth, P. K., & Cowan, K. H. (1995) · PubMed · Cited by 74 · see citing works

Regulation of the mdm2 Oncogene by Thyroid Hormone Receptor

Qi, J.-S., Yuan, Y., Desai-Yajnik, V., & Samuels, H. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.864 · Cited by 66 · see citing works

The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma

Hồng, Miao, M., Xp, Zhang, Xm, Ding, Luo, Guo, Yl, Tan, �., et al. (2006) · 中国生物学文摘 · Cited by 49 · see citing works

Presence of steroid receptors in human soft tissue sarcomas of diverse histological origin.

Chaudhuri, P. K., Walker, M. J., Beattie, C. W., & Gupta, T. K. D. (1980) · PubMed · Cited by 48 · see citing works

Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.

Cerhan, J. R., Vachon, C. M., Habermann, T. M., Ansell, S. M., Witzig, T. E., Kurtin, P. J., Janney, C. A., Zheng, W., Potter, J. D., Sellers, T. A., et al. (2002) · PubMed · Cited by 48 · see citing works

Sex steroid receptors in diverse human tumors.

Kobayashi, S., Mizuno, T., Tobioka, N., 市村, 秀., 佐本, 常., Tanaka, H., Masaoka, A., Wakabayashi, S., Umemura, S., Fukuoka, H., et al. (1982) · PubMed · Cited by 36 · see citing works

Distribution of steroid hormone receptors in human soft tissue sarcomas.

Pk, C., Walker, M. J., Cw, B., & Gupta, T. K. D. (1981) · PubMed · Cited by 34 · see citing works

MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia

Swinney, R. M., Hsu, S., Hirschman, B. A., Chen, T. T.-C., & Tomlinson, G. E. (2005) · Leukemia · doi:10.1038/sj.leu.2403941 · Cited by 30 · see citing works

Distinct promoter usage of mdm2 gene in human breast cancer

Okumura, N., Saji, S., Eguchi, H., Nakashima, S., Saji, S., & Hayashi, S. (2002) · Oncology Reports · doi:10.3892/or.9.3.557 · Cited by 28 · see citing works

Immunological detection of the oestradiol receptor protein in cell lines derived from the lymphatic system and the haematopoietic system: variability of specific hormone binding in vitro

Jakob, F. J., Tony, H. P., Schneider, D., & Thole, H. H. (1992) · Journal of Endocrinology · doi:10.1677/joe.0.1340397 · Cited by 19 · see citing works

Expression of estrogen receptors α and β in soft tissue sarcomas: Immunohistochemical and molecular analysis

Li, X., Hisaoka, M., & Hashimoto, H. (2003) · Pathology International · doi:10.1046/j.1440-1827.2003.01543.x · Cited by 18 · see citing works

Immunohistochemical study of steroid hormones and an estrogen binding assay in malignant soft tissue tumors.

Suda, A., Sato, T., Watanabe, Y., Yamakawa, M., & Imai, Y. (1990) · PubMed · Cited by 7 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

The genetics of the p53 pathway, apoptosis and cancer therapy

Vázquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 674 · see citing works

p53 polymorphisms: cancer implications

Whibley, C., Pharoah, P. D. P., & Hollstein, M. C. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2584 · Cited by 667 · see citing works

Li-Fraumeni Syndrome

Malkin, D. M. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508 · see citing works

Gender Differences in Cancer Susceptibility: An Inadequately Addressed Issue

Dorak, M. T., & Karpuzoglu, E. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00268 · Cited by 492 · see citing works

The p53 orchestra: Mdm2 and Mdmx set the tone

Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450 · see citing works

Recurrent Initiation: A Mechanism for Triggering p53 Pulses in Response to DNA Damage

Batchelor, E., Mock, C. S., Bhan, I., Loewer, A., & Lahav, G. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.016 · Cited by 422 · see citing works

The MDM2-p53 pathway revisited

Nag, S. A., Jiangjiang, Q., Kalkunte, S. S., Ming-hai, W., & Zhang, R. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414 · see citing works

Sex differences in cancer mechanisms

Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P. I., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 370 · see citing works

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm

Soussi, T., & Wiman, K. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.001 · Cited by 366 · see citing works

Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways

Shreeram, S., Demidov, O. N., Hee, W. K., Yamaguchi, H., Onishi, N., Kek, C., Timofeev, O. N., Dudgeon, C., Fornace, A. J., Anderson, C. W., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.07.010 · Cited by 350 · see citing works

The dynamic control of signal transduction networks in cancer cells

Kölch, W., Halász, M., Granovskaya, M., & Kholodenko, B. Ν. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3983 · Cited by 332 · see citing works

Sp1: Emerging roles—Beyond constitutive activation of TATA-less housekeeping genes

Wierstra, I. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.074 · Cited by 337 · see citing works

Sex Differences in Cancer: Epidemiology, Genetics and Therapy

Kim, H.-I., Lim, H., & Moon, A. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.103 · Cited by 315 · see citing works

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246 · see citing works

The ups and downs of p53: understanding protein dynamics in single cells

Batchelor, E., Loewer, A., & Lahav, G. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2604 · Cited by 242 · see citing works

An integrative view on sex differences in brain tumors

Sun, T., Plutynski, A., Ward, S., & Rubin, J. B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1930-2 · Cited by 218 · see citing works

A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans

Bond, G. L., & Levine, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210199 · Cited by 186 · see citing works

The regulation of MDM2 oncogene and its impact on human cancers

Zhao, Y., Yu, H., & Hu, W. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt147 · Cited by 173 · see citing works

An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity

Wynendaele, J., Böhnke, A., Leucci, E., Nielsen, S. J., Lambertz, I., Hammer, S., Sbrzesny, N., Kubitza, D., Wolf, A. A., Gradhand, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0527 · Cited by 171 · see citing works

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170 · see citing works

Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies

Goldstein, I., Marcel, V., Olivier, M., Oren, M., Rotter, V., & Hainaut, P. L. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.63 · Cited by 167 · see citing works

Genome-Wide Sex and Gender Differences in Cancer

Lopes‐Ramos, C. M., Quackenbush, J. F., & DeMeo, D. L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.597788 · Cited by 162 · see citing works

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works

Degrons in cancer

Mészáros, B., Kumar, M., Gibson, T. J., Uyar, B., & Dosztányi, Z. (2017) · Science Signaling · doi:10.1126/scisignal.aak9982 · Cited by 139 · see citing works

Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2

Wiech, M., Olszewski, M. B., Tracz‐Gaszewska, Z., Wawrzynów, B., Żylicz, M., & Żylicz, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051426 · Cited by 132 · see citing works

A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development

Post, S. M., Quintás-Cardama, A., Pant, V., Iwakuma, T., Hamir, A., Jackson, J. G., Maccio, D. R., Bond, G. L., Johnson, D. G., Levine, A. J., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.010 · Cited by 127 · see citing works

Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population

Ørsted, D. D., Bojesen, S. E., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062476 · Cited by 122 · see citing works

Kaposi’s sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies

Ruocco, E., Ruocco, V., Tornesello, M. L., Gambardella, A., Wolf, R., & Buonaguro, L. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2013.01.008 · Cited by 121 · see citing works

Li‐Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition

Valdez, J. M., Nichols, K. E., & Kesserwan, C. A. (2016) · British Journal of Haematology · doi:10.1111/bjh.14461 · Cited by 121 · see citing works

The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

Knappskog, S., Bjørnslett, M., Myklebust, L. M., Huijts, P. E. A., Vreeswijk, M. P. G., Edvardsen, H., Guo, Y., Zhang, X., Yang, M., Ylisaukko‐oja, S. K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.019 · Cited by 118 · see citing works

The Fbw7 and BetaTRCP E3 ubiquitin ligases and their roles in tumorigenesis

Alan, W. L. (2012) · Frontiers in bioscience · doi:10.2741/4045 · Cited by 112 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Gene Disrupts the Oscillation of p53 and MDM2 Levels in Cells

Hu, W., Feng, Z., Ma, L., Wagner, J., Rice, J. J., Stolovitzky, G. A., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2656 · Cited by 112 · see citing works

MDM2 SNP309 and cancer risk: a combined analysis

Wilkening, S., Bermejo, J. L., & Hemminki, K. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm191 · Cited by 109 · see citing works

MDM2 Promoter Polymorphism SNP309 Contributes to Tumor Susceptibility: Evidence from 21 Case-Control Studies

Hu, Z., Jin, G., Wang, L., Chen, F., Wang, X., & Shen, H. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0634 · Cited by 106 · see citing works

Single-nucleotide Polymorphisms in the p53 Signaling PathwayPreprint

Grochola, L. F., Zerón-Medina, J., Mériaux, S. B., & Bond, G. L. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001032 · Cited by 103 · see citing works

Evaluation of well‐differentiated/de‐differentiated liposarcomas by high‐resolution oligonucleotide array‐based comparative genomic hybridization

Tap, W. D., Eilber, F. C., Ginther, C., Dry, S., Reese, N., Smith, K. B., Chen, H., Wu, H., Eilber, F. R., Slamon, D. J., et al. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20835 · Cited by 98 · see citing works

MDM2 SNP309 accelerates colorectal tumour formation in women

Bond, G. L., Menin, C., Bertorelle, R., Alhopuro, P., Aaltonen, L. A., & Levine, A. J. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.043539 · Cited by 97 · see citing works

Population-Based Estimate of the Contribution of TP53 Mutations to Subgroups of Early-Onset Breast Cancer: Australian Breast Cancer Family Study

Mouchawar, J., Korch, C. T., Byers, T., Pitts, T. M., Li, E., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Southey, M. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0851 · Cited by 92 · see citing works

Association of TP53codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients

Toyama, T., Zhang, Z., Nishio, M., Hamaguchi, M., Kondo, N., Iwase, H., Iwata, H., Takahashi, S., Yamashita, H., & Fujii, Y. (2007) · Breast Cancer Research · doi:10.1186/bcr1682 · Cited by 91 · see citing works

The MDM2 gene family

Mendoza, M. J., Mandani, G., & Momand, J. A. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0027 · Cited by 86 · see citing works

MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility

Ellis, N. A., Huo, D., Yildiz, O., Worrillow, L. J., Banerjee, M., Beau, M. M. L., Larson, R. A., Allan, J. M., & Onel, K. (2008) · Blood · doi:10.1182/blood-2007-11-126508 · Cited by 86 · see citing works

TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value

Deben, C., Deschoolmeester, V., Lardon, F., Rolfo, C. D., & Pauwels, P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.019 · Cited by 86 · see citing works

A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation

Brekman, A., Singh, K. E., Polotskaia, A., Kundu, N., & Bargonetti, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2804 · Cited by 71 · see citing works

Do MDM2 SNP309 and TP53 R72P Interact in Breast Cancer Susceptibility? A Large Pooled Series from the Breast Cancer Association Consortium

Schmidt, M. K., Reincke, S., Broeks, A., Braaf, L. M., Hogervorst, F. B. L., Tollenaar, R. A. �. �., Johnson, N., Fletcher, O., Peto, J., Tommiska, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0738 · Cited by 79 · see citing works

MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia

Gryshchenko, I., Hofbauer, S. W., Stöcher, M., Daniel, P. T., Steurer, M., Gaiger, A., Eigenberger, K., Greil, R., & Tinhofer, I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5212 · Cited by 79 · see citing works

Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis

Dongiovanni, P., Fracanzani, A. L., Cairo, G., Megazzini, C., Gatti, S., Rametta, R., Fargion, S. R., & Valenti, L. V. C. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090249 · Cited by 75 · see citing works

An update on the central nervous system manifestations of Li–Fraumeni syndrome

Orr, B. A., Clay, M. R., Pinto, E. M., & Kesserwan, C. A. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02055-3 · Cited by 75 · see citing works

Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis

Economopoulos, K. P., & Sergentanis, T. Ν. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0467-1 · Cited by 73 · see citing works

Haplotype structure and selection of the MDM2 oncogene in humans

Atwal, G. S., Bond, G. L., Metsuyanim, S., Papa, M. Z., Friedman, E., Distelman-Menachem, T., Ben‐Asher, E., Lancet, D., Ross, D. A., Sninsky, J. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610998104 · Cited by 71 · see citing works

Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment

Hrstka, R., Coates, P. J., & Vojtěšek, B. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00634.x · Cited by 71 · see citing works

Genetic Modifiers of the p53 PathwayPreprint

Basu, S., & Murphy, M. E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026302 · Cited by 70 · see citing works

Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival

Bartel, F., Jung, J., Böhnke, A., Gradhand, E., Zeng, K., Thomssen, C., & Hauptmann, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1192 · Cited by 67 · see citing works

It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy

Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 68 · see citing works

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene

Atwal, G. S., Kirchhoff, T., Bond, E. E., Montagna, M., Menin, C., Bertorelle, R., Scaini, M. C., Bartel, F., Böhnke, A., Pempe, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901298106 · Cited by 65 · see citing works

Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival

Toffoli, G., Biason, P., Russo, A. G., Mattia, E. D., Cecchin, E., Hattinger, C. M., Pasello, M., Alberghini, M., Ferrari, C., Scotlandi, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2249 · Cited by 62 · see citing works

Modulation of the Activity of Sp Transcription Factors by Mithramycin Analogues as a New Strategy for Treatment of Metastatic Prostate Cancer

Malek, A. V., Núñez, L. E., Magistri, M., Brambilla, L., Jovic, S., Carbone, G. M., Morís, F., & Catapano, C. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035130 · Cited by 59 · see citing works

Common genetic variants in the TP53 pathway and their impact on cancer

Barnoud, T., Parris, J. L. D., & Murphy, M. E. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz052 · Cited by 60 · see citing works

A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer

Sänchez‐Carbayo, M., Socci, N. D., Kirchoff, T., Erill, N., Offit, K., Bochner, B. H., & Cordon‐Cardo, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0013 · Cited by 58 · see citing works

A functionally significant SNP in TP53 and breast cancer risk in African-American women

Murphy, M. E., Liu, S., Yao, S., Huo, D., Liu, Q., Dolfi, S. C., Hirshfield, K. M., Hong, C. C., Hu, Q., Olshan, A. F., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0007-9 · Cited by 57 · see citing works

The evolution of MDM2 family genes

Momand, J. A., Villegas, A., & Белый, В. А. (2011) · Gene · doi:10.1016/j.gene.2011.06.030 · Cited by 55 · see citing works

Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk

Walsh, C., Miller, C. W., Karlan, B. Y., & Koeffler, H. P. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.10.008 · Cited by 54 · see citing works

Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore

Chua, H. W., Ng, D., Choo, S., Lum, S. S., Li, H., Soh, L. Y., Sabapathy, K., & Seow, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-88 · Cited by 52 · see citing works

Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing

Huang, S., Chen, I.-H., Liao, C., Wang, H., Liou, S.-H., & Hsieh, L. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2008.03.006 · Cited by 52 · see citing works

Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas

Galic, V., Willner, J. B., Wollan, M., Garg, R., Garcia, R. L., Goff, B. A., Gray, H. J., & Swisher, E. M. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20407 · Cited by 52 · see citing works

MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population

Lum, S. S., Chua, H. W., Li, H., Li, W., Rao, N., Wei, J., Shao, Z., & Sabapathy, K. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn024 · Cited by 52 · see citing works

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer

Knappskog, S., Trovik, J., Marcickiewicz, J., Tingulstad, S., Staff, A., Romundstad, P., Hveem, K., VATTEN, L. J., Salvesen, H. B., & Lønning, P. E. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.024 · Cited by 49 · see citing works

Recent Advances in Validating MDM2 as a Cancer Target

Rayburn, E. R., Ezell, S. J., & Zhang, R. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009789124628 · Cited by 48 · see citing works

CRHR1 Polymorphisms Predict Bone Density in Survivors of Acute Lymphoblastic Leukemia

Jones, T. S., Kaste, S. C., Liu, W., Cheng, C., Yang, W., Tantisira, K. G., Pui, C., & Relling, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6399 · Cited by 49 · see citing works

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism

Paulin, F., O'Neill, M. A., McGregor, G., Cassidy, A., Ashfield, A. M., Ali, C., Munro, A. J., Baker, L., Purdie, C. A., Lane, D. P., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-281 · Cited by 48 · see citing works

Impact of a Single Nucleotide Polymorphism in the MDM2 Gene on Neuroblastoma Development and Aggressiveness: Results of a Pilot Study on 239 Patients

Cattelani, S., Defferrari, R., Marsilio, S., Bussolari, R., Candini, O., Corradini, F., Ferrari‐Amorotti, G., Guerzoni, C., Pecorari, L., Menin, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4725 · Cited by 48 · see citing works

The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population

Ezzikouri, S., Feydi, A. E. E., Chafik, A., Benazzouz, M., Kihal, L. E., Afifi, R., Hassar, M., Pineau, P., & Benjelloun, S. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00126.x · Cited by 47 · see citing works

Germline Mutations and Polymorphisms in the Origins of Cancers in Women

Hirshfield, K. M., Rebbeck, T. R., & Levine, A. J. (2010) · Journal of Oncology · doi:10.1155/2010/297671 · Cited by 47 · see citing works

TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility

Thuy, N. B. T., Ucisik-Akkaya, E., Davis, C. F., Morrison, B. A., & Dorak, M. T. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.05.009 · Cited by 47 · see citing works

MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish–Ashkenazi descent

Yarden, R. I., Friedman, E., Metsuyanim, S., Olender, T., Ben‐Asher, E., & Papa, M. Z. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9797-z · Cited by 47 · see citing works

Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia

Xiong, X., Wang, M., Wang, L., Liu, J., Zhao, X., Tian, Z., & Wang, J. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.04.007 · Cited by 45 · see citing works

Probing the Functional Impact of Sequence Variation on p53-DNA Interactions Using a Novel Microsphere Assay for Protein-DNA Binding with Human Cell Extracts

Noureddine, M., Menéndez, D., Campbell, M. R., Bandele, O. J., Horvath, M. M., Wang, X., Pittman, G. S., Chorley, B. N., Resnick, M. A., & Bell, D. A. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000462 · Cited by 45 · see citing works

The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies

Cox, D. G., Deer, D., Guo, Q., Tworoger, S. S., Hankinson, S. E., Hunter, D. J., & Vivo, I. D. (2007) · Cancer Causes & Control · doi:10.1007/s10552-007-9004-x · Cited by 44 · see citing works

Effects of theMDM2promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Knappskog, S., & Lønning, P. E. (2011) · Transcription · doi:10.4161/trns.2.5.16813 · Cited by 40 · see citing works

Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck

Yu, H., Huang, Y., Liu, Z., Wang, L., Li, G., Sturgis, E. M., Johnson, D. G., & Wei, Q. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20806 · Cited by 40 · see citing works

MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling

Wasielewski, M., Nagel, J. H. A., Brekelmans, C. T. M., Klijn, J. G. M., van den Ouweland, A., Meijers-Heijboer, H. E. J., & Schutte, M. E. M. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9407-5 · Cited by 40 · see citing works

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations

Fang, S., Krahe, R., Lozano, G., Han, Y., Chen, W., Post, S. M., Zhang, B., Wilson, C. D., Bachinski, L. L., Strong, L. C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010813 · Cited by 39 · see citing works

Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model

Azzam, G. A., Frank, A. K., Hollstein, M., & Murphy, M. E. (2011) · Cell Cycle · doi:10.4161/cc.10.9.15344 · Cited by 39 · see citing works

MDM2 SNP309 Is Associated with Endometrial Cancer Risk

Terry, K. L., McGrath, M., Lee, I.-M. M., Buring, J. E., & Vivo, I. D. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2872 · Cited by 39 · see citing works

Association of MDM2 SNP309, Age of Onset, and Gender in Cutaneous Melanoma

Firoz, E. F., Warycha, M. A., Zakrzewski, J., Pollens, D., Wang, G., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Manga, P., D, H. O. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2678 · Cited by 38 · see citing works

Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation

Tracz‐Gaszewska, Z., Klimczak, M., Biecek, P., Herok, M., Kosiński, M., Olszewski, M. B., Czerwińska, P., Wiech, M., Wiznerowicz, M., Żylicz, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18899 · Cited by 38 · see citing works

Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population

Sun, T., Lee, G. M., Oh, W. K., Pomerantz, M. M., Yang, M., Xie, W., Freedman, M. L., & Kantoff, P. W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1261 · Cited by 38 · see citing works

Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes

Mehta, M. S., Vázquez, A., Kulkarni, D. A., Kerrigan, J. E., Atwal, G. S., Metsugi, S., Toppmeyer, D., Levine, A. J., & Hirshfield, K. M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1062-1 · Cited by 37 · see citing works

TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype

Zainuddin, N., Berglund, M., Wanders, A., Ren, Z.-P., Amini, R., Lindell, M., Kanduri, M., Roos, G., Rosenquist, R., & Enblad, G. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.022 · Cited by 37 · see citing works

Splicing Up Mdm2 for Cancer Proteome Diversity

Okoro, D. R., Rosso, M., & Bargonetti, J. (2012) · Genes & Cancer · doi:10.1177/1947601912455323 · Cited by 36 · see citing works

MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: A case–control analysis in a Moroccan population

Ezzikouri, S., Feydi, A. E. E., Afifi, R., Kihal, L. E., Benazzouz, M., Hassar, M., Marchio, A., Pineau, P., & Benjelloun, S. (2009) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2009.01.003 · Cited by 36 · see citing works

Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer

Ueda, M., Yamamoto, M., Nunobiki, O., Eisaku, T. O. J. I., Sato, N., Izuma, S., Okamoto, Y., Torii, K., & Noda, S. (2009) · Human Cell · doi:10.1111/j.1749-0774.2009.00068.x · Cited by 35 · see citing works

Association of p73 and MDM2 Polymorphisms With the Risk of Epithelial Ovarian Cancer in Chinese Women

Kang, S., Wang, D., Li, W.-S., Wang, N., Zhou, R., Sun, D.-L., Duan, Y., Li, S., Li, X., & Li, Y. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a130ab · Cited by 34 · see citing works

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

Zienolddiny, S., & Skaug, V. (2011) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s13256 · Cited by 33 · see citing works

Identification of FDA‐approved Drugs that Computationally Bind to MDM2

Warner, W. A., Sanchez, R., Dawoodian, A., Li, E., & Momand, J. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01428.x · Cited by 34 · see citing works

Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma

Reis, A. H. D. O., de Carvalho, I. N. S. R., Damasceno, P. B. D. S., Ferman, S., Lucena, E., López‐Camelo, J. S., Seuánez, H. N., & Vargas, F. R. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24014 · Cited by 33 · see citing works

ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer

Akisik, E. Z., Yazıcı, H., & Dalay, N. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0113-3 · Cited by 33 · see citing works

Regulation of p53 Level by UBE4B in Breast Cancer

Zhang, Y., Lv, Y., Zhang, Y., & Gao, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090154 · Cited by 32 · see citing works

Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator

Okoro, D. R., Arva, N. C., Gao, C., Polotskaia, A., Puente, C., Rosso, M., & Bargonetti, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077643 · Cited by 32 · see citing works

MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients

Phang, B. H., Linn, Y. C., Li, H., & Sabapathy, K. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.007 · Cited by 32 · see citing works

MDM2 SNP309 accelerates colorectal tumour formation in women

Bond, G. L., Menin, C., Bertorelle, R., Alhopuro, P., Aaltonen, L. A., & Levine, A. J. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.043539 · Cited by 97 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Gene Disrupts the Oscillation of p53 and MDM2 Levels in Cells

Hu, W., Feng, Z., Ma, L., Wagner, J., Rice, J. J., Stolovitzky, G. A., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2656 · Cited by 112 · see citing works

A mechanistic study of functional polymorphisms in the MDM2 gene

Solbakken, M. H. (2008) · NORA - Norwegian Open Research Archives

Die G/G-Variante des SNP309 im mdm2 Gen ist mit einem früheren Tumorentstehen in Nierenzellkarzinom-Patientinnen assoziiert

Stoehr, R., Wenners, A. S., Hartmann, A., Bertz, S., Spath, Walter, B., Junker, K., Moch, H., Hintze, R., Denzinger, S., et al. (2016) · German Medical Science (German Research Foundation) · doi:10.3205/16urobay047